Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 7/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20641622 | 1.00 | USP2 (0.50) | USP2SMN1; SMN2EPHX2RECQLGPR119 | |
| SCHEMBL8217782 | 1.00 | USP2 (0.50) | USP2SMN1; SMN2EPHX2RECQLGPR119 | |
| SCHEMBL9566458 | 0.91 | USP2 (0.44) | USP2SMN1; SMN2EPHX2RECQLGPR119 | |
| SCHEMBL9566442 | 0.91 | USP2 (0.44) | USP2SMN1; SMN2EPHX2RECQLGPR119 | |
| SCHEMBL9566391 | 0.91 | USP2 (0.44) | USP2SMN1; SMN2EPHX2RECQLGPR119 | |
| SCHEMBL9566412 | 0.91 | USP2 (0.44) | USP2SMN1; SMN2EPHX2RECQLGPR119 | |
| SCHEMBL9566382 | 0.91 | USP2 (0.44) | USP2SMN1; SMN2EPHX2RECQLGPR119 | |
| SCHEMBL9566436 | 0.91 | USP2 (0.44) | USP2SMN1; SMN2EPHX2RECQLGPR119 | |
| SCHEMBL26873336 | 0.88 | USP2 (0.50) | USP2SMN1; SMN2EPHX2RECQLGPR119 | |
| SCHEMBL24433430 | 0.86 | USP2 (0.49) | USP2SMN1; SMN2EPHX2RECQLGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007064749-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS AND MICROBIAL DISEASES | SCHERING CORPORATION (US) | 2007-06-07 | — | — | WO | disclosed |